Immatics

Today we announced an expanded clinical dataset from the ongoing Phase 1b dose expansion clinical trial for ACTengine® IMA203 and updated Phase 1 dose escalation clinical data on our next-generation ACTengine® IMA203CD8 TCR-T cell therapy. In addition, we reported preclinical data on other next-generation T cell candidates and combination strategies. To read the full announcement, click here: https://lnkd.in/dHUurcEv #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews #SITC

🌏Last week, our employees gathered to celebrate Diwali, bringing the color and brightness of this festival into the office! 🪷Dressed in traditional attire, our team set the stage with vibrant decorations, traditional Indian snacks and festive activities like painting clay lamps called diyas and creating flower rangoli designs. Our talented coworkers even sang traditional Indian songs and danced to some lively Bollywood tunes, adding a fun and authentic touch to the festivities. 💫Thank you to everyone who helped make Diwali at Immatics a beautiful event filled with culture and creativity. #TeamBonding #Together #DiwaliCelebration #FestivalofLights #DiversityAndInclusion

🎉 Last week, the Cyber Valley Health Cluster hosted their official launch event in Tübingen, Germany to unite the forces of science, industry and start-ups. This initiative promotes joint projects between AI experts, scientists and companies to develop innovative solutions for current and future challenges in the healthcare sector. 🔬 Immatics is proud to be a part of the Cyber Valley Health community and facilitate the connection between science and industry in the region of Baden-Württemberg. 👉 Discover more about this exciting initiative and the launch event here: https://lnkd.in/eTiuyn_F #AI #Robotics #Health #HealthcareInnovation #MedicalTechnology #AIforGood #BetterTogether

📢 Starting on Wednesday, November 6th members of the Immatics team will be onsite at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In addition, don’t miss out on our upcoming oral and poster presentations at the conference. Get all the details on dates, times and titles here: https://lnkd.in/eaT7H3rb See you all there! #cancer #immunotherapy #SITC #immunooncology #immunology

Our Chief Medical Officer, Cedrik M. Britten, was recently interviewed for Charlotte Harrison’s article in Nature, “TCR cell therapies vanquish solid tumors — finally.” Read the article for more insights from experts in the dynamic field of TCR cell therapies for solid tumor cancers: https://lnkd.in/eUqcsRKU #solidtumors #cancer #oncology #celltherapy #biotech #immunotherapy

This year at Immatics, our staff motto is #MoveIt and that’s exactly what our team did at the 8th annual Hess Houston Corporate 5K! More than 50 of our colleagues came together to Memorial Park Conservancy to run/walk at Houston’s “Largest Office Party” to promote corporate wellness and team building. After crossing the finish line, our team celebrated at the Immatics tent with healthy snacks, refreshing drinks, live entertainment and more! It was a fun challenge and an excellent opportunity to demonstrate the determination we embody at Immatics in our daily mission of improving the lives of cancer patients. #HESS5K #GetFitHouston #TeamBuilding #EmployeeWellness #memorialpark #runhouston #CorporateWellness

Our Director Clinical Development, Olga Veremchuk, had the pleasure of attending the 65th Congress of the German Society for Gynecology and Obstetrics (DGGG) in Berlin. The DGGG Congress focuses on advancements in gynecology, obstetrics and gynecological cancers, offering a great opportunity for Immatics to engage with the latest clinical research, therapies and treatment strategies aimed at improving cancer care for women. Here are some takeaways from the event: 💡Future treatments for endometrial cancer will focus on using molecular subgroups to better predict outcomes and personalize therapies 💡Newer antibody-drug conjugates (ADCs) are showing positive results in gynecological cancers 💡Next generation immuno-oncology trials, including bispecific antibodies, are now underway Our Immatics team is excited to apply these insights as we continue to advance our TCR-based immunotherapies. #DGGG2024 #Gynecology #Obstetrics #WomensHealth #Innovation #Berlin #Collaboration

In case you missed it: Last week, we announced updated Phase 1b clinical data on ACTengine® IMA203 TCR-T targeting PRAME in metastatic melanoma patients. We also provided an update on SUPRAME, the upcoming registration-enabling Phase 3 trial to evaluate IMA203 in cutaneous melanoma patients. Read the full announcement here: https://lnkd.in/eF56m5ni #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews

Today we announced a $150 million public offering. As a biotechnology company with several TCR-based cell therapy and bispecific product candidates moving through clinical development, this financing will further support us in the advancement of our targeted immunotherapies for patients with solid tumors. Read the full press release here: https://lnkd.in/dF8TD_2i #financing #biotech #oncology #cancer #corporatenews #financialnews #healthcare

Today we announced updated Phase 1b clinical data on ACTengine® IMA203 in metastatic melanoma patients and provided an update on the upcoming Phase 3 trial, “SUPRAME.” To read the full announcement, click here: https://lnkd.in/eF56m5ni We will also host a conference call and webcast today, October 10th at 9:00 am EDT / 3:00 pm CEST. The link to the webcast is available in the comments section below and in the press release. #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews